GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...

GSK agrees to acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences, while Sanofi is offloading 20 mature medicines and three manufacturing sites to Cheplapharm. GSK and ...

Three years ago, when Pharmaceutical Executive last profiled Wendy Short Bartie, she was newly installed as senior vice ...

Cellectis has announced that its board of directors have approved a strategic transformation to become an in vivo gene ...

Consolidation to a day-to-day “Novo” name seeks consistent global recognition while retaining Novo Nordisk A/S as the legal ...

Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing ...

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in ...

The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...

Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...

Specifically, patients with high cortisol levels face unique challenges that GLP-1s may not be able to tackle. Dr. Elena Christofides: We have been doing a significant amount of medical education — ...

Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following ...

Ultragenyx is reviewing program disposition and implementing significant expense reductions as brokerages cut price targets ...